EXPRESSION AND IDENTIFICATION OF CD6 LIGANDS IN PSORIASIS

牛皮癣是一种慢性炎症性皮肤病，可引起 儿童和成人的毁容皮疹。免疫组织学 银屑病斑块研究显示增生性增生 表皮角质形成细胞与活化的T淋巴细胞并列 抗原提呈细胞包括表皮朗格汉斯细胞和 真皮树突状细胞。多条证据表明T 淋巴细胞在银屑病发病机制中起主要作用 并包括研究表明：有效的T细胞免疫抑制 环孢素和FK506(他克莫司)等药物可导致消退 在停药后复发的牛皮癣。 T细胞共刺激分子对之间的相互作用 银屑病患者皮肤中的专业和组织APC配体被假设 在慢性疾病的始发和延续中起重要作用 银屑病期间观察到的炎性变化。T细胞的相互作用 皮肤免疫细胞表面分子及其配体的表达 包括但不限于LFA-1(CD11a/CD18)/ICAM-1和CD28/BB1。 体外黏附试验证明了黏附相互作用 T细胞表面分子CD6和CD6细胞表面配体之间的相互作用 在干扰素激活的角质形成细胞中表达。CD6有 以前被证明在T细胞应答过程中很重要 名义抗原、异体抗原和自身抗原。我们现在假设相互作用 皮肤免疫细胞中T细胞CD6和CD6配体的表达可能代表着一种新的 在启动和/或永久化 银屑病的炎症反应。为了确定 CD6/CD6配体相互作用在银屑病皮肤中的作用 建议资助研究CD6和CD6配体的表达 在银屑病患者皮肤中表达，并对这些皮肤进行生化鉴定 免疫细胞CD6配体。

Psoriasis is a chronic inflammatory skin disease which causes disfiguring skin eruptions in children and adults. Immunohistologic studies of psoriatic plaques show hyperplastic proliferation of epidermal keratinocytes juxtaposed to activated T lymphocytes and antigen presenting cells including epidermal Langerhans cells and dermal dendritic cells. Multiple lines of evidence suggest that T lymphocytes are of primary importance in the pathogenesis of psoriasis and include studies showing that: potent T-cell immunosuppressive medications such as cyclosporin and FK506 (tacrolimus) cause regression of psoriasis which returns when the medication is discontinued. Interactions between pairs of T-cell co-stimulatory molecules and professional and tissue APC ligands in psoriatic skin are hypothesized to be important in the initiation and perpetuation of the chronic inflammatory changes observed during psoriasis. Interactions of T-cell surface molecules and their ligands expressed on skin immunocytes include but are not limited to LFA-1 (CD11a/CD18)/ICAM-1, and CD28/BB1. In vitro adhesion assays have demonstrated adhesive interactions between the T-cell surface molecule CD6, and CD6 cell surface ligands expressed in gamma-interferon activated keratinocytes. CD6 has previously been shown to be important during T cell responses to nominal, allo and self antigen. We now hypothesize that interactions of T cell CD6 and CD6 ligands in skin immunocytes may represent a novel pathway which is important in initiation and/or perpetuation of the inflammatory response seen in psoriasis. In order to determine the role of CD6/CD6 ligand interactions in psoriatic skin, this application proposes funding to characterize the expression of CD6 and CD6 ligands expressed in psoriatic skin, and to biochemically identify these skin immunocyte CD6 ligands.